ArticleFrontiers in bioengineering and biotechnology2025
Engineering human bone marrow-derived mesenchymal stromal cell aggregates for enhanced extracellular vesicle secretion in a vertical-wheel bioreactor.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Electrical Stimulation of Human Adipose Tissue-Derived Mesenchymal Stem Cells and Schwann Cells for Regulating Extracellular Vesicle Biogenesis and Inflammation.Bioengineering (Basel, Switzerland) · 2026Article
- Additive Manufacturing for Extracellular Vesicle Therapeutics: Engineering Strategies for Production, Isolation, and Delivery.Advanced healthcare materials · 2026Review
- Article
- Modeling and targeting the hostile physicochemical niche in bone metastasis: from experimental platforms to niche-directed therapy.Frontiers in cell and developmental biology · 2026Review
- Mechanobiological modulation: physiological pressure preconditioning boosts the paracrine-driven lymphangiogenic capacity of bone marrow mesenchymal stem cells.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human mesenchymal stem/stromal cells (hMSCs) hold significant regenerative potential due to their anti-inflammatory and pro-angiogenic secretome. Three-dimensional (3D) hMSC aggregates secrete extracellular vesicles (EVs) with enhanced immunomodulatory properties compared to 2D cultures. However, the clinical translation of hMSC-EVs remains limited by low production yield. This study investigates scalable EV generation from 3D hMSC aggregates in a novel Vertical-Wheel Bioreactor (VWBR), leveraging shear stress-mediated biochemical cues to enhance EV biogenesis and cargo relevant to nerve regeneration. Methods: Bone marrow-derived hMSCs were cultured as 3D aggregates in VWBRs and exposed to two different culture media-αMEM/FBS (serum-containing) and DMEM/F12/B27 (serum-free)-under three agitation speeds (25, 40, and 64 rpm). Metabolite analysis and qRT-PCR were performed to assess metabolic activity and EV biogenesis, focusing on ESCRT machinery markers. EVs were isolated and evaluated for yield, size, markers, and microRNA cargo. Functional assays were conducted to measure the effects on EVs on Schwann cells under LPS-induced neural inflammation. Results: VWBR culture resulted in increased expression of EV biogenesis genes and glycolytic pathway markers compared to static culture. The αMEM/FBS (serum-containing) condition was more robust than DMEM/F12/B27 (serum-free) condition. EV yield (EV number per cell) increased by 3-10 fold (in serum-containing medium) in VWBR compared to static culture, with particle sizes ranging from 120-180 nm and appropriate EV marker expression. microRNA-sequencing showed upregulation of miR-29a-3p, miR-451a, miR-224-5p, miR-16-5p, miR-133a-3p, and miR-143-3p, indicating enhanced EV biogenesis, metabolic reprogramming, and immunomodulatory potential. Functionally, VWBR-derived EVs modulated inflammatory gene expression in Schwann cells exposed to LPS. Discussion: VWBR-driven hydrodynamics promotes EV biogenesis from 3D hMSC aggregates, improving metabolic activity, EV cargo relevance, and functional efficacy. The resulting EVs exhibit therapeutic cargo capable of modulating neural inflammation. These findings advance understanding of dynamic aggregation on metabolic cues and EV production, demonstrating a scalable strategy for generating therapeutically potent hMSC-EVs for neuropathic and regenerative applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.